114  Effect of siponimod on cognitive processing speed in SPMS patients with active and non-active disease

• Published in: Journal of neurology, neurosurgery and psychiatry Vol. 93; no. 6; p. A136
• Main Authors: Penner, K, Giovannoni, G, Cree, BAC, Fox, RJ, Bar-ors, A, Gold, R, Vermesch, P, Piani-Meier, D, Ritter, S
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group Ltd 01.06.2022; BMJ Publishing Group LTD
• Subjects: ABN Abstracts 2021; Births; Hospitals; Multiple sclerosis; Neurosciences; Pregnancy; Womens health
• ISSN: 0022-3050; 1468-330X
• DOI: 10.1136/jnnp-2022-ABN.439

BackgroundSiponimod significantly reduced the relative risk of 3-month (m) confirmed disability progression (CDP) by 21% and 6mCDP by 26% versus placebo in the EXPAND core study and showed significant benefits on cognitive processing speed (CPS) using the Symbol Digit Modalities Test (SDMT).ObjectivesTo evaluate the effect of siponimod on CPS in active (aSPMS) and non-active (naSPMS) patients from EXPAND core study.MethodsThis subgroup analysis included aSPMS patients (siponimod, n=516; placebo, n=263) and naSPMS patients (siponimod, n=557; placebo, n=270). Change in SDMT score; time to 6m confirmed ≥4-points cognitive worsening/improvement (6mCW/6mCI) on SDMT and the proportion of patients with worsened, stable and improved SDMT scores at M24 were analysed.ResultsChange in SDMT (95% Cl) versus placebo from baseline to M24 in aSPMS and naSPMS groups was2.34 (0.66; 4.02) and 2.44 (0.67; 4.22), respectively, consistent with overall EXPAND core population. In aSPMS patients, siponimod reduced risk of 6mCW by 27% (p=0.06) and improved chances of 6mCI by 62% (p=0.007) versus placebo. Corresponding values in the naSPMS group were: 6mCW, 24% (p=ns) and 6mCI, 19% (p=ns).ConclusionsSiponimod was associated with relevant benefits in CPS as measured by change in SDMT in patients with active and non-active SPMS.teresasawtell@novartis.com82